登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C18H28N2O · HCl · H2O
化学文摘社编号:
分子量:
342.90
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
产品名称
布比卡因, Pharmaceutical Secondary Standard; Certified Reference Material
InChI
1S/C18H28N2O.ClH.H2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3;;/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21);1H;1H2
SMILES string
O.Cl.CCCCN1CCCCC1C(=O)Nc2c(C)cccc2C
InChI key
HUCIWBPMHXGLFM-UHFFFAOYSA-N
grade
certified reference material
pharmaceutical secondary standard
agency
USP 1078507
traceable to Ph. Eur. B1160000
API family
bupivacaine
CofA
current certificate can be downloaded
technique(s)
HPLC: suitable
gas chromatography (GC): suitable
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-30°C
Quality Level
正在寻找类似产品? 访问 产品对比指南
Application
盐酸布比卡因可用作药物标准品,用于通过荧光法和高效液相色谱法测定药物制剂中的分析物。
这些二级标准品是合格的认证标准物质(CRM)。它们适用于多种分析应用,包括但不限于药物释放测试、药物的定性和定量分析方法开发、食品和饮料质量控制检测以及其他校准需求。
Biochem/physiol Actions
钠通道阻滞剂,局部麻醉药。
General description
用于质量控制的制药二级标准品,为制药实验室和制造商制备内部工作标准品提供了一种方便、高性价比的替代方案。
Other Notes
在我们的NMR在线平台ChemisTwin®上可以找到本品对应的数字化标准物质。您可使用ChemisTwin®上的数字等效品鉴定您的样品并进行定量分析(使用数字化外标)。可查看该物质的NMR谱图,只需点击几次鼠标,就能进行在线样品比对。欢迎点击了解更多,开启免费试用之旅。
想要查看本品的检验报告示例,请在下框中输入LRAA6762。这只是一个示例证书,可能与您收到的批次不符。
该认证标准物质(CRM)根据ISO 17034和ISO/IEC 17025进行生产和认证。有关此CRM使用的所有信息均可在检验报告上找到。
Analysis Note
These secondary standards offer multi-traceability to the USP and EP primary standards, where they are available.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 1 Inhalation - Acute Tox. 2 Dermal - Acute Tox. 2 Oral
存储类别
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Development and validation of an HPLC method to determine the stability of fentanyl citrate and bupivacaine hydrochloride mixtures in infusion solutions.
Piekarski M, et al.
European Journal of Hospital Pharmacy-Science and Practice, 19(5), 447-451 (2012)
Spectrophotometric method for determination of bupivacaine hydrochloride in pharmaceutical preparations
Corciova A
European Chemical Bulletin, 2(8), 554-557 (2013)
Ilin Kuo et al.
Anesthesiology, 118(6), 1350-1361 (2013-03-06)
In vitro observations support the lipid sink theory of therapeutic action by confirming the capacity of lipid emulsions to successfully uptake bupivacaine from aqueous media. However, competing hypotheses and some in/ex vivo small animal studies suggest that a metabolic or
Kejian Shi et al.
Anesthesia and analgesia, 116(4), 804-809 (2013-03-06)
While lipid emulsion may reverse the systemic toxicity of bupivacaine, the pharmacokinetics and tissue distribution of bupivacaine after lipid emulsion infusion are not clear. In this study, we assessed the influence of lipid emulsion administration on the pharmacokinetics and tissue
Brian M Ilfeld et al.
Anesthesia and analgesia, 117(5), 1248-1256 (2013-10-11)
Currently available local anesthetics approved for single-injection peripheral nerve blocks have a maximum duration of <24 hours. A liposomal bupivacaine formulation (EXPAREL, Pacira Pharmaceuticals, Inc., San Diego, CA), releasing bupivacaine over 96 hours, recently gained Food and Drug Administration approval
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持